Related Experiment Video

Updated: May 3, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

2.8K

Percutaneous Hemodynamic Support (Impella) in Patients with Advanced Heart Failure and/or Cardiogenic Shock Not

Wei Liu1, Venkata Kishore Mukku2, Syed Gilani2

  • 1Cardiology Department, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

The International Journal of Angiology : Official Publication of the International College of Angiology, Inc
|January 18, 2014
PubMed

Insights

Impella support aids high-risk PCI in hemodynamically unstable patients, including those with cardiogenic shock. This approach shows promise for improving outcomes in complex cardiac cases not covered by prior trials.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Mechanical Circulatory Support

Background:

  • Previous trials like PROTECT I and II excluded critically ill patients with severe hemodynamic instability.
  • High-risk percutaneous coronary intervention (PCI) patients with cardiogenic shock or decompensated heart failure (HF) require advanced hemodynamic support.
  • The efficacy of Impella support in this extremely high-risk population remains understudied.

Purpose of the Study:

  • To evaluate the efficacy and safety of Impella 2.5 support in patients undergoing high-risk PCI who presented with severe hemodynamic instability.
  • To assess Impella's role as a hemodynamic support tool or a bridge to other therapies in a population excluded from major trials.

Main Methods:

  • A consecutive series of 10 extremely high-risk patients with advanced HF and/or cardiogenic shock underwent urgent PCI with Impella 2.5 support.
  • Patients included those with cardiac arrest and acute myocardial infarction.
  • Hemodynamic stability during PCI was monitored.

Main Results:

  • All 10 patients received successful Impella implantation and maintained hemodynamic stability throughout the high-risk PCI procedure.
  • Within one month, 20% (2 patients) died, and one patient experienced limb ischemia.
  • Impella provided effective hemodynamic support during PCI in this challenging patient cohort.

Conclusions:

  • Impella 2.5 can serve as a crucial tool for hemodynamic support during high-risk PCI in patients with advanced heart failure or cardiogenic shock.
  • It may also function as a bridge to left ventricular assist device implantation, potentially leading to good recovery.
  • Larger studies are warranted to further investigate the utility of Impella in this non-randomizable, high-risk population.

Keywords:
cardiogenic shockheart failureleft ventricle assisting devicepercutaneous coronary intervention

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
2.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805